{"id":38394,"date":"2025-08-01T16:53:36","date_gmt":"2025-08-01T08:53:36","guid":{"rendered":"https:\/\/flcube.com\/?p=38394"},"modified":"2025-08-01T16:53:37","modified_gmt":"2025-08-01T08:53:37","slug":"bms-q2-earnings-reflect-strategic-investments-maintains-full-year-revenue-growth-outlook","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38394","title":{"rendered":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook"},"content":{"rendered":"\n<p>US major Bristol-Myers Squibb (BMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.<\/p>\n\n\n\n<p><strong>Q2 Performance and Key Product Sales<\/strong><br>The company\u2019s growth portfolio, which includes its immuno-oncology (IO) portfolio, recorded a 17% YOY increase in revenue to USD 6.6 billion. Notable sales during the quarter included:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breyanzi (lisocabtagene maraleucel)<\/strong>: A CD19-targeted CAR T cell therapy with a 122% increase to USD 344 million.<\/li>\n\n\n\n<li><strong>Reblozyl (luspatercept)<\/strong>: An anemia therapy with a 33% increase to USD 568 million.<\/li>\n\n\n\n<li><strong>Camzyos (mavacamten)<\/strong>: A treatment for symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) with an 86% increase to USD 260 million.<\/li>\n\n\n\n<li><strong>Opdivo (nivolumab)<\/strong>: A PD-1 inhibitor with a 7% increase to USD 2.56 billion.<\/li>\n<\/ul>\n\n\n\n<p>Additionally, the schizophrenia treatment <strong>Cobenfy (xanomeline\/trospium chloride)<\/strong> launched strongly, generating USD 35 million in sales from the US market alone. The off-patent blood thinner <strong>Eliquis (apixaban)<\/strong>, marketed in partnership with Pfizer, continued its growth with a 6% increase to USD 3.68 billion. A new addition to the portfolio was <strong>Qvantig<\/strong>, a subcutaneous injection version of the PD-1 nivolumab.<\/p>\n\n\n\n<p><strong>Strategic Initiatives and Partnerships<\/strong><br>CEO Dr. Christopher Boerner emphasized that the company is entering a crucial period of accelerated growth, driven by strategic partnerships and pivotal data readouts. In addition to the BioNTech collaboration, BMS announced a joint venture with Bain Capital, forming \u201cNewCo\u201d and outlicensing five immunology assets, including afimetoran (TLR7\/8), and products targeting TYK2, IL-2-CD25, IL-10, and IL-18. BMS holds approximately a 20% stake in NewCo.<\/p>\n\n\n\n<p><strong>Clinical Trials and Future Prospects<\/strong><br>Boerner highlighted that the company is entering a data-rich period, with expectations of 7 registration assets and 7 meaningful life cycle management opportunities over the next 12 to 24 months. Key upcoming data readouts include pivotal trials for Cobenfy in treating Alzheimer\u2019s disease psychosis. Additionally, the TYK2 inhibitor <strong>Sotyktu (deucravacitinib)<\/strong>, approved for moderate-to-severe plaque psoriasis, has been filed for approval globally, including in China, for a new indication of active psoriatic arthritis. The US FDA has set a March 6, 2026, Prescription Drug User Fee Act goal date for this regulatory decision.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-Q2-2025-Earnings-Press-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BMY-Q2-2025-Earnings-Press-Release.\"><\/object><a id=\"wp-block-file--media-391b50ba-425e-4540-a220-6b17fceb5bc6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-Q2-2025-Earnings-Press-Release.pdf\">BMY-Q2-2025-Earnings-Press-Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-Q2-2025-Earnings-Press-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-391b50ba-425e-4540-a220-6b17fceb5bc6\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-2025-Q2-Results-Investor-Presentation.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BMY-2025-Q2-Results-Investor-Presentation.\"><\/object><a id=\"wp-block-file--media-c4f96126-b9a5-42b2-a362-06d9bc3660e5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-2025-Q2-Results-Investor-Presentation.pdf\">BMY-2025-Q2-Results-Investor-Presentation<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BMY-2025-Q2-Results-Investor-Presentation.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c4f96126-b9a5-42b2-a362-06d9bc3660e5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[429,428,27,849],"class_list":["post-38394","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bms","tag-bristol-myers-squibb","tag-finanical-reports","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38394\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook\" \/>\n<meta property=\"og:description\" content=\"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38394\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T08:53:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T08:53:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook\",\"datePublished\":\"2025-08-01T08:53:36+00:00\",\"dateModified\":\"2025-08-01T08:53:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0110.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Finanical Reports\",\"NYSE: BMY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38394#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38394\",\"name\":\"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0110.webp\",\"datePublished\":\"2025-08-01T08:53:36+00:00\",\"dateModified\":\"2025-08-01T08:53:37+00:00\",\"description\":\"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38394\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0110.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0110.webp\",\"width\":1080,\"height\":608,\"caption\":\"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38394#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook - Insight, China&#039;s Pharmaceutical Industry","description":"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38394","og_locale":"en_US","og_type":"article","og_title":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook","og_description":"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.","og_url":"https:\/\/flcube.com\/?p=38394","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-01T08:53:36+00:00","article_modified_time":"2025-08-01T08:53:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38394#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38394"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook","datePublished":"2025-08-01T08:53:36+00:00","dateModified":"2025-08-01T08:53:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38394"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38394#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","keywords":["BMS","Bristol-Myers Squibb","Finanical Reports","NYSE: BMY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38394#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38394","url":"https:\/\/flcube.com\/?p=38394","name":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38394#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38394#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","datePublished":"2025-08-01T08:53:36+00:00","dateModified":"2025-08-01T08:53:37+00:00","description":"US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues of USD 12.27 billion, flat at 0% year-on-year (YOY) excluding currency effects. Earnings per share (EPS GAAP) decreased by 22%, primarily due to a USD 1.5 billion upfront payment to BioNTech under their June partnership for the PD-L1xVEGF-A bispecific antibody BNT327. Despite this impact, BMS raised its full-year revenue guidance to USD 46.5-47.5 billion from USD 45.8-46.8 billion, driven by better-than-expected legacy portfolio sales. Non-GAAP EPS guidance was slightly revised downward to USD 6.35-6.65 from USD 6.70-7.00, reflecting investments in strategic partnerships.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38394#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38394"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38394#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","width":1080,"height":608,"caption":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38394#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0110.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38394"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38394\/revisions"}],"predecessor-version":[{"id":38398,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38394\/revisions\/38398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38397"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}